Evidence map›Paper›PMID 31149543›Full record

ArticleInternational cancer conference journal2019

Marked response to nivolumab combined with external radiation therapy for metastatic renal cell carcinoma: report of two cases.

Yuto Matsushita, Katsumasa Nakamura, Hiroshi Furuse, Kenji Ichinohe, Hideaki Miyake

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International cancer conference journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuto Matsushita1Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Katsumasa Nakamura2Department of Radiation Oncology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hiroshi FuruseDepartment of Urology, Chutoen General Medical Center, Kakegawa, Japan.
Kenji IchinoheDepartment of Radiation Oncology, Chutoen General Medical Center, Kakegawa, Japan.
Hideaki Miyake1Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although nivolumab has been regarded as a standard agent for patients with previously treated advanced renal cell carcinoma (RCC), a significant proportion of these patients fail to achieve a response to nivolumab. In recent years, several studies have reported the favorable therapeutic impact of combined therapy with immune checkpoint inhibitors and radiotherapy on a wide variety of advanced malignant tumors, such as melanoma and lung cancer; however, the significance of this combined treatment for advanced RCC patients has not been well characterized. Here, we report two patients with metastatic RCC showing a marked response to nivolumab and external radiation therapy, including one with an abscopal response, after progression on prior treatment with multiple targeted agents. Based on the clinical courses of these two patients suggesting additive or synergistic efficacies on combining radiation with nivolumab, it might be worthwhile to consider the addition of radiotherapy for metastatic RCC patients treated with nivolumab.

Indexed as

Abscopal effectMetastatic renal cell carcinomaNivolumabRadiation

Identifiers

PMID31149543
PMCPMC6498363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.